NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026
Key Highlights
- ➤NeOnc CEO Amir F. Heshmatpour to address life sciences investment at Abu Dhabi summit
- ➤Abu Dhabi authorized NEO100 across adult Phase 1, Phase 1b and Phase 2 protocols
- ➤NEO100 authorization covers progressive or recurrent Grade III or IV gliomas
- ➤Abu Dhabi cleared NEO212, extending NeOnc’s UAE clinical development footprint
- ➤NeOnc is establishing NuroMENA for Middle East collaboration and partnerships
Expert Statements
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings, Inc.
“For patients and families facing devastating brain cancers, the urgency is real. Our responsibility is to match that urgency with rigorous science and the capital needed to move clinical development forward.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings, Inc.
“Abu Dhabi is bringing healthcare leadership, research and investment together to advance that work. We are grateful to the Department of Health – Abu Dhabi for its rigorous and collaborative review of our clinical programs. At NeOnc, we are building international relationships with a clear purpose: to advance investigational therapies and work toward broader patient access. The Summit is an opportunity to discuss how investment can help promising science reach the next stage of development.”
CALABASAS, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer, will speak at the Abu Dhabi Future Health Summit 2026, October 20 to 22 at the ADNEC Centre in Abu Dhabi, United Arab Emirates. His participation comes as NeOnc builds its UAE clinical development presence following Department of Health – Abu Dhabi authorizations for both NEO100 and NEO212.
Mr. Heshmatpour will bring the perspective of a biotechnology executive and investor working to connect promising science with the capital and international partnerships needed to advance clinical development. With more than 25 years of experience in finance, corporate development and mergers and acquisitions, he leads NeOnc’s capital formation and international strategy and is Founder and Managing Director of AFH Holding & Advisory, LLC.
Get started
Create a free account to read the full story.